Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Connection Between General Practitioner's (GP's) Estimation of Cardiovascular Risk and Theoretical Calculation in France

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: December 24, 2009
Last updated: September 14, 2010
Last verified: September 2010
The purpose of this study is to evaluate connection between GP's estimation of cardiovascular risk and theoretical calculation.

Cardiovascular Risk

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Connection Between GP's Estimation of Cardiovascular Risk and Theoretical Calculation in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate connection between GP's estimation of cardiovascular risk and theoretical calculation (according to guidelines and validated scales (such as risk score profile in the Framingham Heart study or the SCORE risk estimation)) [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To estimate the number of cardiovascular risk patients, that have not been identified [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
  • To characterize those patients according to their theoretical cardiovascular risk (high, medium, low) [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
  • to reveal GP's estimation of cardiovascular risk is especially driven by LDL [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Estimated Enrollment: 13502
Study Start Date: December 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Adults ≥ 50 years old


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Primary care

Inclusion Criteria:

  • Adults 50 years old and over, visiting their GPs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01039402

  Show 277 Study Locations
Sponsors and Collaborators
Study Chair: Pr Eric BRUCKERT APHP Paris - France, Hôpital La Pitié-Salpétriêre
Principal Investigator: Mrs Geneviève BONNELYE KantarHealth - France
  More Information

Responsible Party: MC MD, AstraZeneca Identifier: NCT01039402     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2009/3 
Study First Received: December 24, 2009
Last Updated: September 14, 2010
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
cardiovascular risk
Observational, descriptive study processed this record on December 06, 2016